Your browser is no longer supported. Please, upgrade your browser.
Settings
BPTS [NASD]
Biophytis SA
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand11.38M Perf Week2.62%
Market Cap98.09M Forward P/E- EPS next Y- Insider Trans- Shs Float10.99M Perf Month-15.49%
Income- PEG- EPS next Q- Inst Own2.61% Short Float0.00% Perf Quarter-36.20%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.01 Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range8.00 - 18.50 Perf YTD-47.76%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-53.41% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low7.75% ATR0.71
Employees25 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)42.15 Volatility0.25% 3.32%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.00 Prev Close8.62
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume3.22K Price8.62
Recom- SMA20-8.86% SMA50-21.66% SMA200-32.03% Volume0 Change0.00%
Aug-02-21 02:00AM  
Jul-19-21 05:00PM  
Jul-12-21 12:53PM  
11:10AM  
02:00AM  
Jul-08-21 02:00AM  
Jun-30-21 05:00PM  
05:00PM  
Jun-18-21 08:00PM  
May-12-21 02:00AM  
May-11-21 02:00AM  
Apr-30-21 02:00AM  
Apr-29-21 02:00AM  
Apr-27-21 02:00AM  
Apr-26-21 02:00AM  
Apr-13-21 05:00PM  
Mar-22-21 03:00AM  
Mar-19-21 06:00PM  
Mar-10-21 10:08PM  
Feb-26-21 02:00AM  
Feb-17-21 02:00AM  
Feb-15-21 02:00AM  
Feb-10-21 09:16AM  
04:40AM  
04:28AM  
02:00AM  
Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases and the treatment of severe respiratory failure in patients suffering from COVID-19. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Its second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry ager elated macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is based in Paris, France.